UK, drugmakers at odds over drug pricing plans
A trade group representing British drugmakers said that discussions between the industry and the UK government over a new drug pricing plan have concluded without an agreement. “Despite good faith and...
View ArticleLB Pharmaceuticals is said to be working on IPO for schizophrenia drug
The schizophrenia biotech LB Pharmaceuticals is working with the investment bank Leerink Partners on a potential initial public offering, Endpoints News has learned. LB could publicly file its IPO...
View ArticleViking’s obesity readout; George Church lab closer to creating human eggs;...
Welcome back to Endpoints Weekly! This weekend’s edition is packed with interesting tidbits, from a George Church lab’s progress toward creating human eggs, to an approved new use for Novo Nordisk’s...
View ArticleLB Pharmaceuticals seeks IPO as cash runs dry for looming Phase 3...
The first biotech IPO in six-plus months will be a sharp test of whether investors are truly ready to buy into young biotech companies whose success remains uncertain. On Friday, LB Pharmaceuticals ...
View ArticleFDA suspends license for Valneva's chikungunya vaccine amid safety concerns
The FDA on Friday recommended pausing use of Valneva's chikungunya vaccine, citing one death "directly attributable" to Ixchiq and hospitalizations, while noting that the vaccine "appears to be causing...
View ArticleMerck looks to modest HIV business as a $5B underdog
With Keytruda’s patent cliff looming, Merck has to find ways to shore up its business, and it’s betting that HIV will be one of those areas. “We just recently went through our HIV portfolio with ...
View ArticleAbbVie to buy psychedelic drug from partner Gilgamesh
AbbVie is further delving into neuroscience with an up to $1.2 billion acquisition of a psychedelic compound from its partner Gilgamesh Pharmaceuticals. The Chicago-area drug giant will buy...
View ArticleAkeso touts Phase 3 wins for two separate inflammatory drugs
Two monoclonal antibodies from Akeso were successful in Phase 3 trials as treatments for inflammatory conditions, bolstering the company’s pipeline outside of oncology. The Chinese biotech reported...
View ArticleMannKind to buy scPharmaceuticals for up to $360M; Arnatar launches with $52M
Plus, news about Vaxxas, Mid-Atlantic BioTherapeutics, Incyclix Bio and Invivyd: 🫀MannKind to buy scPharmaceuticals: The Connecticut biopharma is paying $5.35 per share upfront in cash, plus a...
View ArticleBeOne to get $885M upfront in royalty deal over Amgen’s Imdelltra
BeOne Medicines is the latest biopharma to take advantage of the burgeoning royalty financing market. The drugmaker, recently renamed from BeiGene, will get $885 million upfront from Royalty Pharma,...
View ArticleArgenx's Vyvgart clears Phase 3 in new subset of myasthenia gravis patients
Argenx will seek FDA approval of Vyvgart to treat a new category of generalized myasthenia gravis patients after the drug passed a pivotal trial. Intravenous Vyvgart significantly improved the impact...
View ArticleFDA begins publishing adverse event data on a daily basis
The FDA is speeding up its publishing of adverse event data potentially linked to drugs and vaccines, moving from quarterly reports to daily updates, the agency announced Friday. Known as the FDA...
View ArticleOverall survival in cancer drug trials: New FDA draft guidance sets the bar
Overall survival data should be included in all randomized cancer drug clinical trials, the FDA said in new draft guidance. Calling overall survival (OS) "a gold standard endpoint," the 15-page
View ArticleHHS winds down decades-old pediatric brain cancer collaboration
The National Cancer Institute said it will stop funding a 26-year-old collaboration with academic centers to help accelerate new pediatric brain tumor treatments. The HHS subagency said it will instead...
View ArticleBARDA awards nearly $20M to flu vaccine maker Osivax
French vaccine maker Osivax has won an award of at least $19.5 million from HHS to scale up development of its pandemic flu vaccine, a sign that the government is continuing to back some other ...
View ArticleLilly plans GLP-1 pill filing after trial success in obesity and diabetes
Eli Lilly’s oral GLP-1 helped patients with both obesity and type 2 diabetes lose up to 9.6% of their weight after about 17 months, new Phase 3 data show. Armed with data from another successful ...
View ArticleNeuro biotech Leal Therapeutics raises $30M Series A
The brain-focused startup Leal Therapeutics has raised a modest Series A round to push its lead neurology drugs deeper into the clinic, its CEO exclusively told Endpoints News. CEO Asa Abeliovich, a...
View ArticleWhy Cheryl Pegus joined weight loss startup FlyteHealth
Cheryl Pegus has held leadership positions at major corporations like Pfizer, Walgreens, Aetna, Walmart, and JPMorgan Health. Now, she's joining the startup world. Pegus is now the CEO of the...
View ArticleIncannex’s stock rallies on anxiety disorder data; Appia Bio closes its doors
Plus, news about InxMed, Marker Therapeutics, PDS Biotech, Shattuck Labs, Pfizer, BioInvent and Celyad Oncology: 💊 Incannex’s psilocybin treatment passes Phase 2 anxiety trial: The biotech’s...
View ArticleNovartis pays $30M to Leqembi creator for access to blood-brain barrier tech
Novartis inked a blood-brain barrier partnership with the Swedish inventor of Leqembi, the Alzheimer's drug marketed by Eisai and Biogen, further building on its recent neuroscience dealmaking. The...
View Article